X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs GLENMARK PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH GLENMARK PHARMA PANACEA BIOTECH/
GLENMARK PHARMA
 
P/E (TTM) x 176.4 11.9 1,478.6% View Chart
P/BV x 3.9 3.2 124.3% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 PANACEA BIOTECH   GLENMARK PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
GLENMARK PHARMA
Mar-17
PANACEA BIOTECH/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs149993 15.0%   
Low Rs82729 11.3%   
Sales per share (Unadj.) Rs84.1325.5 25.8%  
Earnings per share (Unadj.) Rs-18.339.3 -46.6%  
Cash flow per share (Unadj.) Rs-6.748.7 -13.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs83.7159.2 52.6%  
Shares outstanding (eoy) m61.25282.17 21.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.42.6 51.9%   
Avg P/E ratio x-6.321.9 -28.8%  
P/CF ratio (eoy) x-17.217.7 -97.4%  
Price / Book Value ratio x1.45.4 25.5%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m7,074242,991 2.9%   
No. of employees `0002.813.0 21.2%   
Total wages/salary Rs m1,44916,408 8.8%   
Avg. sales/employee Rs Th1,874.17,083.9 26.5%   
Avg. wages/employee Rs Th527.01,265.4 41.6%   
Avg. net profit/employee Rs Th-407.7855.1 -47.7%   
INCOME DATA
Net Sales Rs m5,15491,857 5.6%  
Other income Rs m100374 26.7%   
Total revenues Rs m5,25492,230 5.7%   
Gross profit Rs m-76620,367 -3.8%  
Depreciation Rs m7112,644 26.9%   
Interest Rs m1,5032,373 63.3%   
Profit before tax Rs m-2,88115,724 -18.3%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771-810 -218.8%   
Tax Rs m173,827 0.4%   
Profit after tax Rs m-1,12111,088 -10.1%  
Gross profit margin %-14.922.2 -67.1%  
Effective tax rate %-0.624.3 -2.4%   
Net profit margin %-21.812.1 -180.3%  
BALANCE SHEET DATA
Current assets Rs m3,81068,746 5.5%   
Current liabilities Rs m8,36527,027 31.0%   
Net working cap to sales %-88.445.4 -194.6%  
Current ratio x0.52.5 17.9%  
Inventory Days Days15685 183.2%  
Debtors Days Days6796 70.4%  
Net fixed assets Rs m14,48024,132 60.0%   
Share capital Rs m61282 21.7%   
"Free" reserves Rs m90344,643 2.0%   
Net worth Rs m5,12744,925 11.4%   
Long term debt Rs m5,83245,363 12.9%   
Total assets Rs m19,433117,639 16.5%  
Interest coverage x-0.97.6 -12.0%   
Debt to equity ratio x1.11.0 112.6%  
Sales to assets ratio x0.30.8 34.0%   
Return on assets %2.011.4 17.2%  
Return on equity %-21.924.7 -88.6%  
Return on capital %3.619.1 19.0%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,53956,152 2.7%   
Fx outflow Rs m9428,084 11.7%   
Net fx Rs m59748,068 1.2%   
CASH FLOW
From Operations Rs m5996,574 9.1%  
From Investments Rs m-438-7,124 6.1%  
From Financial Activity Rs m-3035,432 -5.6%  
Net Cashflow Rs m-1411,992 -7.1%  

Share Holding

Indian Promoters % 74.5 48.3 154.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 6.9 8.7%  
FIIs % 1.3 34.4 3.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.5 224.8%  
Shareholders   10,259 56,727 18.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 16, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS